Loading...
XSHG
600518
Market cap4.04bUSD
Sep 22, Last price  
2.07CNY
1D
-4.15%
1Q
10.64%
Jan 2017
-88.35%
IPO
82.36%
Name

Kangmei Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
P/E
3,338.68
P/S
5.52
EPS
0.00
Div Yield, %
—
Shrs. gr., 5y
23.67%
Rev. gr., 5y
-14.63%
Revenues
5.19b
+6.47%
584,613,750825,606,6161,294,056,7331,727,164,1512,377,160,9013,308,801,6406,080,507,22511,165,154,81813,358,728,51715,949,188,76918,066,827,95221,642,324,07017,578,618,64017,065,079,13911,445,545,8105,412,007,9614,152,521,0994,180,150,3294,874,016,1435,189,137,000
Net income
9m
-91.64%
72,646,31399,889,496146,109,126294,575,387501,508,534715,522,7121,005,031,0181,441,191,4881,879,816,9942,285,879,1212,756,734,5983,340,403,6404,100,926,148374,492,320007,917,900,6230102,521,2318,574,000
CFO
-428m
L+34.68%
133,131,86368,318,922162,553,1073,015,266119,466,024669,185,655574,964,0931,008,350,2051,674,010,6281,132,203,880508,863,2251,603,189,3511,842,794,237305,616,7272,882,044,9861,031,392,101214,205,1020-317,521,754-427,633,000
Dividend
Aug 28, 20190.024 CNY/sh

Profile

Kangmei Pharmaceutical Co., Ltd. produces and sells Chinese medicines in China. It also offers chemical drug products; and operates hospitals and Chinese medicine pharmacies. The company was founded in 1997 and is headquartered in Puning, China.
URL
http://www.kangmei.com.cn/
IPO date
Mar 19, 2001
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
5,189,137
6.47%
4,874,016
16.60%
4,180,150
0.67%
Cost of revenue
4,709,957
5,056,352
4,223,335
Unusual Expense (Income)
NOPBT
479,180
(182,336)
(43,185)
NOPBT Margin
9.23%
Operating Taxes
22,568
6,800
30,270
Tax Rate
4.71%
NOPAT
456,612
(189,135)
(73,454)
Net income
8,574
-91.64%
102,521
 
Dividends
(750)
Dividend yield
0.00%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
15,828
26,137
64,736
Long-term debt
189,904
376,326
398,261
Deferred revenue
555,779
618,683
653,982
Other long-term liabilities
17,792
1,661,378
1,834,587
Net debt
(773,222)
(655,379)
(1,045,792)
Cash flow
Cash from operating activities
(427,633)
(317,522)
CAPEX
(61,712)
(99,745)
Cash from investing activities
139,915
(37,642)
Cash from financing activities
174,815
FCF
2,039,749
(1,054,686)
859,680
Balance
Cash
977,923
1,056,689
1,507,515
Long term investments
1,031
1,152
1,274
Excess cash
719,497
814,141
1,299,781
Stockholders' equity
(11,992,771)
(10,477,421)
14,239,068
Invested Capital
19,885,872
20,052,233
7,436,657
ROIC
2.29%
ROCE
6.05%
EV
Common stock shares outstanding
14,289,438
10,252,123
13,863,867
Price
2.34
25.81%
1.86
-15.45%
2.20
-28.80%
Market cap
33,437,285
75.35%
19,068,949
-37.48%
30,500,507
-28.80%
EV
32,698,609
18,446,462
29,490,133
EBITDA
819,166
163,840
322,505
EV/EBITDA
39.92
112.59
91.44
Interest
22,410
56,154
78,897
Interest/NOPBT
4.68%